• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19.

作者信息

Sharun Khan, Dhama Kuldeep, Patel Shailesh Kumar, Pathak Mamta, Tiwari Ruchi, Singh Bhoj Raj, Sah Ranjit, Bonilla-Aldana D Katterine, Rodriguez-Morales Alfonso J, Leblebicioglu Hakan

机构信息

Division of Surgery, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, 243 122, Uttar Pradesh, India.

Division of Pathology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, 243 122, Uttar Pradesh, India.

出版信息

Ann Clin Microbiol Antimicrob. 2020 May 30;19(1):23. doi: 10.1186/s12941-020-00368-w.

DOI:10.1186/s12941-020-00368-w
PMID:32473642
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7261036/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41b6/7261385/a62190d3e5dc/12941_2020_368_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41b6/7261385/e54dbc345777/12941_2020_368_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41b6/7261385/a62190d3e5dc/12941_2020_368_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41b6/7261385/e54dbc345777/12941_2020_368_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41b6/7261385/a62190d3e5dc/12941_2020_368_Fig2_HTML.jpg

相似文献

1
Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19.伊维菌素，一种治疗新型冠状病毒/新冠肺炎的新候选药物。
Ann Clin Microbiol Antimicrob. 2020 May 30;19(1):23. doi: 10.1186/s12941-020-00368-w.
2
Ivermectin and COVID-19: Keeping Rigor in Times of Urgency.伊维菌素与新冠肺炎：在紧急时刻保持严谨
Am J Trop Med Hyg. 2020 Jun;102(6):1156-1157. doi: 10.4269/ajtmh.20-0271.
3
Ivermectin and COVID-19: A report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses.伊维菌素与新冠病毒：《抗病毒研究》上的一篇报告、广泛关注、美国食品药品监督管理局的警告、致编辑的两封信以及作者的回应
Antiviral Res. 2020 Jun;178:104805. doi: 10.1016/j.antiviral.2020.104805. Epub 2020 Apr 21.
4
Inefficiency of Sera from Mice Treated with Pseudotyped SARS-CoV to Neutralize 2019-nCoV Infection.用假型化严重急性呼吸综合征冠状病毒（SARS-CoV）处理的小鼠血清中和2019新型冠状病毒（2019-nCoV）感染的低效性
Virol Sin. 2020 Jun;35(3):340-343. doi: 10.1007/s12250-020-00214-5. Epub 2020 Mar 31.
5
Asymptomatic coronavirus infection: MERS-CoV and SARS-CoV-2 (COVID-19).无症状冠状病毒感染：中东呼吸综合征冠状病毒和严重急性呼吸综合征冠状病毒2（新型冠状病毒肺炎）
Travel Med Infect Dis. 2020 May-Jun;35:101608. doi: 10.1016/j.tmaid.2020.101608. Epub 2020 Feb 27.
6
Diagnosis and Management of First Case of COVID-19 in Canada: Lessons Applied From SARS-CoV-1.加拿大首例 COVID-19 病例的诊断与管理：从 SARS-CoV-1 中吸取的经验教训。
Clin Infect Dis. 2020 Nov 19;71(16):2207-2210. doi: 10.1093/cid/ciaa227.
7
Response to "Quantitative Clinical Pharmacology INPUT to SARS-CoV-2 Therapeutics Should be Based on Robust Data".对《SARS-CoV-2治疗药物的定量临床药理学输入应基于可靠数据》的回应。
Clin Pharmacol Ther. 2020 Aug;108(2):189. doi: 10.1002/cpt.1873. Epub 2020 May 20.
8
From SARS-CoV to SARS-CoV-2: The response and challenge of forensic infectious disease autopsy.从严重急性呼吸综合征冠状病毒到严重急性呼吸综合征冠状病毒2：法医传染病尸检的应对与挑战
Fa Yi Xue Za Zhi. 2020 Feb;36(1):1-3. doi: 10.12116/j.issn.1004-5619.2020.01.001. Epub 2020 Feb 25.
9
A cluster of pneumonia associated with the SARS-Cov-2 outside of Wuhan related to a house-warming banquet.武汉以外与一次乔迁宴相关的新冠肺炎聚集性病例。
J Infect. 2020 Jul;81(1):147-178. doi: 10.1016/j.jinf.2020.03.034. Epub 2020 Apr 10.
10
Pangolins Harbor SARS-CoV-2-Related Coronaviruses.穿山甲携带 SARS-CoV-2 相关冠状病毒。
Trends Microbiol. 2020 Jul;28(7):515-517. doi: 10.1016/j.tim.2020.04.001. Epub 2020 Apr 6.

引用本文的文献

1
Ivermectin decreases inflammation and imiquimod-induced psoriasis-like skin lesions in rat via targeting TLR4/p65 NF-κB.伊维菌素通过靶向Toll样受体4/核因子κB（TLR4/p65 NF-κB）减轻大鼠炎症及咪喹莫特诱导的银屑病样皮肤损伤。
Iran J Basic Med Sci. 2025;28(6):808-814. doi: 10.22038/ijbms.2025.83254.18008.
2
Repositioning anthelmintics for the treatment of inflammatory-based pathological conditions.重新定位驱虫药用于治疗基于炎症的病理状况。
Inflammopharmacology. 2025 Feb;33(2):551-571. doi: 10.1007/s10787-024-01605-w. Epub 2024 Nov 26.
3
Unlocking insights: Navigating COVID-19 challenges and Emulating future pandemic Resilience strategies with strengthening natural immunity.

本文引用的文献

1
Successful recovery of COVID-19 pneumonia in a patient from Colombia after receiving chloroquine and clarithromycin.哥伦比亚患者接受氯喹和克拉霉素治疗后，新冠肺炎肺炎成功康复。
Ann Clin Microbiol Antimicrob. 2020 Apr 24;19(1):16. doi: 10.1186/s12941-020-00358-y.
2
Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment?羟氯喹啉和伊维菌素：用于新冠病毒化学预防和治疗的协同组合？
J Am Acad Dermatol. 2020 Jun;82(6):e221. doi: 10.1016/j.jaad.2020.04.017. Epub 2020 Apr 10.
3
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
解锁见解：应对新冠疫情挑战并通过增强自然免疫力效仿未来大流行的韧性策略。
Heliyon. 2024 Jul 17;10(15):e34691. doi: 10.1016/j.heliyon.2024.e34691. eCollection 2024 Aug 15.
4
In Silico Comparative Analysis of Ivermectin and Nirmatrelvir Inhibitors Interacting with the SARS-CoV-2 Main Protease.伊维菌素和奈玛特韦抑制剂与 SARS-CoV-2 主蛋白酶相互作用的计算机比较分析。
Biomolecules. 2024 Jun 25;14(7):755. doi: 10.3390/biom14070755.
5
A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19.关于COVID-19的药物制剂、免疫疗法和支持性疗法的全面综述。
Narra J. 2022 Dec;2(3):e92. doi: 10.52225/narra.v2i3.92. Epub 2022 Dec 8.
6
COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery.新型冠状病毒肺炎（COVID-19）治疗方法：旧药新用的临床应用及基于靶点的药物发现的未来策略
Genes Dis. 2023 Jul;10(4):1402-1428. doi: 10.1016/j.gendis.2022.12.019. Epub 2023 Apr 7.
7
Innovative, rapid, high-throughput method for drug repurposing in a pandemic-A case study of SARS-CoV-2 and COVID-19.大流行中药物重新利用的创新、快速、高通量方法——以严重急性呼吸综合征冠状病毒2和2019冠状病毒病为例
Front Pharmacol. 2023 Mar 1;14:1130828. doi: 10.3389/fphar.2023.1130828. eCollection 2023.
8
Electrochemical Characterisation and Confirmation of Antioxidative Properties of Ivermectin in Biological Medium.电化学特性分析和伊维菌素在生物介质中抗氧化性能的确认。
Molecules. 2023 Feb 24;28(5):2113. doi: 10.3390/molecules28052113.
9
An Automated Strategy to Handle Antigenic Variability in Immunisation Protocols, Part II: In Vitro Transcribed mRNA Vector Design for Inoculation Against Infectious Agent Variants.免疫方案中应对抗原变异性的自动化策略，第二部分：针对传染性病原体变异体接种的体外转录 mRNA 载体设计。
Methods Mol Biol. 2023;2575:323-340. doi: 10.1007/978-1-0716-2716-7_17.
10
Acceptance and adverse effects following COVID-19 vaccination among the health care workers at a health care centre in the most backward district of India.印度最落后地区一家医疗中心医护人员接种新冠疫苗后的接受情况及不良反应
J Family Med Prim Care. 2022 Jun;11(6):3224-3229. doi: 10.4103/jfmpc.jfmpc_2370_21. Epub 2022 Jun 30.
美国食品药品监督管理局批准的药物伊维菌素可抑制 SARS-CoV-2 的体外复制。
Antiviral Res. 2020 Jun;178:104787. doi: 10.1016/j.antiviral.2020.104787. Epub 2020 Apr 3.
4
Ivermectin Inhibits Bovine Herpesvirus 1 DNA Polymerase Nuclear Import and Interferes with Viral Replication.伊维菌素抑制牛疱疹病毒1型DNA聚合酶的核输入并干扰病毒复制。
Microorganisms. 2020 Mar 13;8(3):409. doi: 10.3390/microorganisms8030409.
5
The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer.广谱抗病毒药物伊维菌素靶向宿主核转运进口蛋白α/β1 异二聚体。
Antiviral Res. 2020 May;177:104760. doi: 10.1016/j.antiviral.2020.104760. Epub 2020 Mar 3.
6
Current therapeutic applications and pharmacokinetic modulations of ivermectin.伊维菌素的当前治疗应用及药代动力学调节
Vet World. 2019 Aug;12(8):1204-1211. doi: 10.14202/vetworld.2019.1204-1211. Epub 2019 Aug 8.
7
Lack of efficacy of ivermectin for prevention of a lethal Zika virus infection in a murine system.伊维菌素预防致死性寨卡病毒感染的疗效在鼠系统中缺失。
Diagn Microbiol Infect Dis. 2019 Sep;95(1):38-40. doi: 10.1016/j.diagmicrobio.2019.03.012. Epub 2019 Mar 29.
8
Ivermectin treatment inhibits the replication of Porcine circovirus 2 (PCV2) in vitro and mitigates the impact of viral infection in piglets.伊维菌素治疗可抑制猪圆环病毒 2（PCV2）的体外复制，并减轻仔猪感染病毒的影响。
Virus Res. 2019 Apr 2;263:80-86. doi: 10.1016/j.virusres.2019.01.010. Epub 2019 Jan 15.
9
Ivermectin inhibits DNA polymerase UL42 of pseudorabies virus entrance into the nucleus and proliferation of the virus in vitro and vivo.伊维菌素抑制伪狂犬病病毒进入细胞核的 DNA 聚合酶 UL42 和病毒在体外和体内的增殖。
Antiviral Res. 2018 Nov;159:55-62. doi: 10.1016/j.antiviral.2018.09.010. Epub 2018 Sep 26.
10
Ivermectin: enigmatic multifaceted 'wonder' drug continues to surprise and exceed expectations.伊维菌素：神秘的多面“神奇”药物不断带来惊喜并超出预期。
J Antibiot (Tokyo). 2017 May;70(5):495-505. doi: 10.1038/ja.2017.11. Epub 2017 Feb 15.